Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

500 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.
Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, Wadleigh M, DeAngelo DJ, Stone RM, Sakamaki H, Appelbaum FR, Döhner H, Antin JH, Soiffer RJ, Cutler C. Koreth J, et al. Among authors: sakamaki h. JAMA. 2009 Jun 10;301(22):2349-61. doi: 10.1001/jama.2009.813. JAMA. 2009. PMID: 19509382 Free PMC article. Review.
Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study.
Sakamaki H, Miyawaki S, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Takahashi M, Ogawa Y, Honda S, Ohno R. Sakamaki H, et al. Int J Hematol. 2010 Mar;91(2):284-92. doi: 10.1007/s12185-009-0483-2. Int J Hematol. 2010. PMID: 20063133 Clinical Trial.
A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Matsushima T, Takahashi M, Ogawa Y, Honda S, Ohno R; Japan Adult Leukemia Study Group AML 97 Study. Miyawaki S, et al. Among authors: sakamaki h. Cancer. 2005 Dec 15;104(12):2726-34. doi: 10.1002/cncr.21493. Cancer. 2005. PMID: 16284985 Free article. Clinical Trial.
Normal karyotype acute myeloid leukemia with the CD7+ CD15+ CD34+ HLA-DR + immunophenotype is a clinically distinct entity with a favorable outcome.
Iriyama N, Asou N, Miyazaki Y, Yamaguchi S, Sato S, Sakura T, Maeda T, Handa H, Takahashi M, Ohtake S, Hatta Y, Sakamaki H, Honda S, Taki T, Taniwaki M, Miyawaki S, Ohnishi K, Kobayashi Y, Naoe T. Iriyama N, et al. Among authors: sakamaki h. Ann Hematol. 2014 Jun;93(6):957-63. doi: 10.1007/s00277-014-2013-4. Epub 2014 Jan 19. Ann Hematol. 2014. PMID: 24441947
A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study.
Miyawaki S, Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K, Usui N, Sakura T, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno R. Miyawaki S, et al. Among authors: sakamaki h. Blood. 2011 Feb 24;117(8):2366-72. doi: 10.1182/blood-2010-07-295279. Epub 2010 Dec 29. Blood. 2011. PMID: 21190996 Free article. Clinical Trial.
Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study.
Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, Okumura H, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno R. Ohtake S, et al. Among authors: sakamaki h. Blood. 2011 Feb 24;117(8):2358-65. doi: 10.1182/blood-2010-03-273243. Epub 2010 Aug 6. Blood. 2011. PMID: 20693429 Free article. Clinical Trial.
CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21).
Iriyama N, Hatta Y, Takeuchi J, Ogawa Y, Ohtake S, Sakura T, Mitani K, Ishida F, Takahashi M, Maeda T, Izumi T, Sakamaki H, Miyawaki S, Honda S, Miyazaki Y, Taki T, Taniwaki M, Naoe T. Iriyama N, et al. Among authors: sakamaki h. Leuk Res. 2013 Sep;37(9):1021-6. doi: 10.1016/j.leukres.2013.05.002. Epub 2013 Jun 28. Leuk Res. 2013. PMID: 23810283 Clinical Trial.
Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era.
Takamatsu H, Honda S, Miyamoto T, Yokoyama K, Hagiwara S, Ito T, Tomita N, Iida S, Iwasaki T, Sakamaki H, Suzuki R, Sunami K. Takamatsu H, et al. Among authors: sakamaki h. Cancer Sci. 2015 Feb;106(2):179-85. doi: 10.1111/cas.12594. Epub 2015 Feb 6. Cancer Sci. 2015. PMID: 25530023 Free PMC article.
CD25 expression on residual leukemic blasts at the time of allogeneic hematopoietic stem cell transplant predicts relapse in patients with acute myeloid leukemia without complete remission.
Ikegawa S, Doki N, Kurosawa S, Yamaguchi T, Sakaguchi M, Harada K, Yamamoto K, Hino Y, Shingai N, Senoo Y, Hattori K, Igarashi A, Najima Y, Kobayashi T, Kakihana K, Sakamaki H, Haraguchi K, Okuyama Y, Ohashi K. Ikegawa S, et al. Among authors: sakamaki h. Leuk Lymphoma. 2016;57(6):1375-81. doi: 10.3109/10428194.2015.1099644. Epub 2015 Dec 23. Leuk Lymphoma. 2016. PMID: 26422713
500 results